SecBot SecBot
SECBOTREPLAY Home › Report › CGEN

CGEN · Compugen reported Q3 2026 net loss of $5.8M ($0.06 per share), narrower…

COMPUGEN LTD · 6-K filed Nov 9, 2026 at 07:01 ET

At the news

NEUTRALIMPACT 4/10

6-K filed Nov 9, 2026 at 07:01 ET

Compugen reported Q3 2026 net loss of $5.8M ($0.06 per share), narrower than the $7.0M loss in Q3 2025, on revenue of $3.8M (up from $1.9M). The EPS of -$0.06 beat the consensus estimate of -$0.09. Cash of $117.5M is expected to fund operations into 2029. Key pipeline catalysts include MAIA-ovarian results by end of Q1 2027 and Phase 3 rilvegostomig data from AstraZeneca in H2 2027.

  • Q3 2026 net loss of $5.8M ($0.06 per share) vs $7.0M ($0.07) in Q3 2025
  • Revenue of $3.8M vs $1.9M in Q3 2025, driven by Gilead license revenue recognition
  • Cash and equivalents of $117.5M as of Sep 30, 2026; runway into 2029
  • MAIA-ovarian trial (COM701) fully enrolled; results expected by end of Q1 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access